Hummingbird Diagnostics to Present New Findings Linking Ribosome Quality Control Pathway to Liquid Biopsy Biomarkers for Lung Cancer at EACR
Data highlight a mechanistic link between ribosomal stress pathways and biomarker generation, with potential implications for patient stratification and treatment response
Hummingbird Diagnostics GmbH, a molecular diagnostics company focused on blood-based tests for early disease detection and precision medicine, today announced that it will present new findings supporting the biological and clinical relevance of its liquid biopsy RNA biomarkers in lung cancer at the upcoming EACR Congress, taking place June 8-11 in Budapest, Hungary.
The poster provides new insight into how ribosome stress and activation of ribosome quality control (RQC) pathways drive the generation of specific small RNA biomarkersdetectable in liquid biopsy samples from lung cancer patients.
The data show that challenging the protein synthesis machinery in cancer cells leads to ribosome stalling and collisions, thereby triggering RQC pathways that generate biomarker precursor molecules. These are subsequently secreted and matured extracellularly, enabling detection in patient-derived samples. The findings further suggest a link between ribosomal RNA methylation dynamics, biomarker biology, and cellular sensitivity to ribotoxic stress.
